Crescent Biopharma, Inc.
CBIO · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $1,605 | $14,949 | $15,917 | $7,409 |
| - Cash | $35 | $42 | $48 | $90 |
| + Debt | $37 | $1 | $1 | $2 |
| Enterprise Value | $1,608 | $14,908 | $15,870 | $7,321 |
| Revenue | $0 | $0 | $0 | $1 |
| % Growth | -100% | -86.7% | -93.5% | – |
| Gross Profit | $0 | $0 | $0 | $1 |
| % Margin | – | 100% | 100% | 100% |
| EBITDA | $0 | -$39 | -$47 | -$63 |
| % Margin | – | -391,213.6% | -62,927.6% | -5,447.9% |
| Net Income | -$71 | -$37 | -$47 | -$63 |
| % Margin | – | -368,994.2% | -62,251.7% | -5,469% |
| EPS Diluted | -0.59 | -0.58 | -0.89 | -1.23 |
| % Growth | -1.7% | 34.8% | 27.6% | – |
| Operating Cash Flow | -$31 | -$35 | -$46 | -$57 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$31 | -$35 | -$47 | -$58 |